Magnesium Glycinate for Headache Prophylaxis
Magnesium (including magnesium glycinate) is a reasonable option for migraine prophylaxis in otherwise healthy adults, though it is not included in the most recent 2025 American College of Physicians guideline as a first-line agent. The 2024 VA/DoD guideline does recommend magnesium for episodic migraine prevention 1, and multiple randomized controlled trials support its efficacy.
Evidence-Based Recommendation
Guideline Support
The 2024 VA/DoD clinical practice guideline explicitly lists magnesium as an option for preventing episodic migraine 1. However, the most recent 2025 ACP guideline does not include magnesium in its comparative effectiveness review, focusing instead on medications like β-blockers (metoprolol, propranolol), antiseizure medications (topiramate, valproate), ARBs (candesartan, telmisartan), CGRP antagonists, and others 2.
Clinical Trial Evidence
Multiple randomized controlled trials demonstrate magnesium's effectiveness:
- Dosing: 600 mg daily of magnesium (typically as magnesium citrate or dicitrate) reduced migraine attack frequency by 41.6% versus 15.8% for placebo over 12 weeks 3
- Efficacy parameters: Magnesium significantly reduces attack frequency, severity, and number of migraine days 4, 3
- Meta-analysis findings: Oral magnesium alleviates both frequency and intensity of migraine (OR = 0.20 and 0.27 respectively) 5
- Evidence grade: Systematic review provides Grade C (possibly effective) evidence for migraine prevention 6
Magnesium Glycinate Specifically
The FDA label for magnesium glycinate indicates it is a dietary supplement (~93.75% active ingredient) 7 with the standard disclaimer that it is "not intended to diagnose, treat, cure, or prevent any disease" 7. This means magnesium glycinate is not FDA-approved as a medication for migraine prophylaxis, though it can be used as a magnesium supplement.
Practical Implementation
When to Consider Magnesium
- Adults with episodic migraine (2-14 headache days per month)
- Patients who prefer natural/supplement-based approaches
- Those who cannot tolerate or wish to avoid prescription medications
- Patients with documented or suspected magnesium deficiency 8, 9
Dosing Strategy
- Standard dose: 600 mg elemental magnesium daily 3
- Duration: Minimum 12 weeks to assess efficacy 3
- Formulation: While studies primarily used magnesium citrate or dicitrate, magnesium glycinate may offer better bioavailability and tolerability 8
Expected Outcomes
- Reduction in attack frequency becomes apparent after 9-12 weeks 3
- May also decrease attack duration, intensity, and acute medication use 4
- Effects on cortical blood flow and visual evoked potentials suggest both vascular and neurogenic mechanisms 4
Important Caveats
Limitations
- Not first-line per 2025 ACP: The most recent guideline prioritizes other agents with stronger evidence 2
- Supplement status: As a dietary supplement, magnesium glycinate lacks the regulatory oversight of prescription medications 7
- Side effects: Diarrhea (18.6%) and gastric irritation (4.7%) are common 3
- Contraindications: Do not use if pregnant or lactating per FDA label 7
When to Choose Prescription Medications Instead
If the patient has:
- High-frequency episodic migraine (≥4 attacks/month) requiring more robust prevention
- Significant disability affecting quality of life
- Failed magnesium trial after 12 weeks
- Comorbid conditions that would benefit from prescription prophylaxis (e.g., hypertension → β-blockers or ARBs)
Consider starting with prescription medications (β-blockers, topiramate, candesartan) per 2025 ACP guidelines 2 if the patient requires more aggressive prophylaxis, reserving magnesium for those preferring supplements or as adjunctive therapy.
Monitoring
- Assess response at 12 weeks: frequency, severity, and disability
- Check for gastrointestinal side effects
- Consider switching to prescription prophylaxis if inadequate response